Document is current
Any future updates will be listed below
-
Authors
Zorn, Stefanie
Bounds, Rebecca
Williamson, Alice https://orcid.org/0000-0002-7599-9301
Lawler, Katherine
Hanssen, Ruth
Keogh, Julia
Henning, Elana
Smith, Miriam
Fielding, Barbara A.
Umpleby, A. Margot
Yasmeen, Summaira https://orcid.org/0000-0001-5470-2081
Marti-Solano, Maria https://orcid.org/0000-0003-0373-8927
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
Wabitsch, Martin https://orcid.org/0000-0001-6795-8430
Collet, Tinh-Hai https://orcid.org/0000-0002-3243-1222
Farooqi, I. Sadaf https://orcid.org/0000-0001-7609-3504
-
Funding
Funding for this research was provided by:
Wellcome Trust (RGAG339)
- License Information
-
More Information
Article History
Received: 10 November 2024
Accepted: 22 August 2025
First Online: 16 October 2025
Competing interests
: I.S.F. has consulted for Eli Lilly, Novo Nordisk, Nodthera, Congruence Therapeutics, Sanofi and Rhythm Pharmaceuticals on weight loss drugs. T.H.C. has consulted for Rhythm Pharmaceuticals. S.Z. has received honorary fees from Rhythm Pharmaceuticals. M.W. has consulted for Novo Nordisk, Chiesi and Rhythm Pharmaceuticals. R.H. has consulted or received honorary fees from Novo Nordisk and Rhythm Pharmaceuticals. All the other authors declare no competing interests.
